RxDoctor Payments Data

Matthias Karajannis

Pediatric Hematology-Oncology · New York, NYNPI 1174643167

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,740 of the $2,740 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, AstraZeneca.

$2,740in general payments, 2019–2025

Across 1 payment — averaging $2740.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
$2,070,191in research payments, 2019–2025

Across 31 payments — averaging $66,780 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$1.8M
  • Genentech, Inc.$300K
  • F. Hoffmann-la Roche AG$426

What the payments were for

  • Consulting fees$2,740100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$2,740

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,740 in reported general payments places this provider in the 70th percentile of 196 pediatric hematology-oncology providers in New York.

See all pediatric hematology-oncology providers in New York

Other pediatric hematology-oncology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →